Browsing by Author "Demirci, U."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    ArticlePublicationOpen Access
    Micro-a-fluidics ELISA for rapid CD4 cell count at the point-of-care
    (Nature, 2014-01-22) Wang, S.; Tasoglu, S.; Chen, P. Z.; Chen, M.; Akbaş, Ragıp; Wach, S.; Ozdemir, C. İ.; Gurkan, U. A.; Giguel, F. F.; Kuritzkes, D. R.; Demirci, U.; Civil Engineering; AKBAŞ, Ragıp
    HIV has become one of the most devastating pathogens in human history. Despite fast progress in HIV-related basic research, antiretroviral therapy (ART) remains the most effective method to save AIDS patients' lives. Unfortunately, ART cannot be universally accessed, especially in developing countries, due to the lack of effective treatment monitoring diagnostics. Here, we present an inexpensive, rapid and portable micro-a-fluidic platform, which can streamline the process of an enzyme-linked immunosorbent assay (ELISA) in a fully automated manner for CD4 cell count. The micro-a-fluidic CD4 cell count is achieved by eliminating operational fluid flow via “moving the substrate”, as opposed to “flowing liquid” in traditional ELISA or microfluidic methods. This is the first demonstration of capturing and detecting cells from unprocessed whole blood using the enzyme-linked immunosorbent assay (ELISA) in a microfluidic channel. Combined with cell phone imaging, the presented micro-a-fluidic ELISA platform holds great promise for offering rapid CD4 cell count to scale up much needed ART in resource-constrained settings. The developed system can be extended to multiple areas for ELISA-related assays.
  • Placeholder
    Book ChapterPublicationMetadata only
    Microchip ELISA coupled with cell phone to detect ovarian cancer HE4 biomarker in urine
    (Springer Science+Business Media, 2014) Wang, S.; Akbaş, Ragıp; Demirci, U.; Civil Engineering; AKBAŞ, Ragıp
    Ovarian cancer is a leading cause of death from gynecologic cancers in the USA, and early diagnosis can potentially increase 5-year survival rate. Detection of biomarkers derived from hyperplasia of epithelial tissue by enzyme-linked immunosorbent assay (ELISA) proves to be a practical way of early diagnosis of ovarian cancer. However, ELISA is commonly performed in a laboratory setting, and it cannot be used in a clinical setting for on-site consultation. We have shown a microchip ELISA that detects HE4, an ovarian cancer biomarker, from urine using a cell phone integrated with a mobile application for imaging and data analysis. In microchip ELISA, HE4 from urine was first absorbed on the surface; the primary and secondary antibodies were subsequently anchored on the surface via immuno-reaction; and addition of substrate led to color development because of enzymatic labeling. The microchip after color development was imaged using a cell phone, and the color intensity was analyzed by an integrated mobile application. By comparing with an ELISA standard curve, the concentration of HE4 was reported on the cell phone screen. The presented microchip ELISA coupled with a cell phone is portable as opposed to traditional ELISA, and this method can facilitate the detection of ovarian cancer at the point-of-care (POC).